Call
+918447748545

Published on: Jul 22, 2020
2 minute read
By: Dr Rajan Choudhary

The Oxford Vaccine

Recently we wrote a blog on the success of an RNA vaccine against SARS-CoV-2, the virus responsible for COVID-19. Within just a few weeks of that incredible research breakthrough, researchers at Oxford University’s Jenner Institute have announced a COVID vaccine that has induced remarkable immune response against the virus.

This study was published in the Lancet, one of the most prestigious medical journals in the world, and a simple summary suggests the vaccine has no early safety concern and is able to induce a strong immune response with both T cells and B cell/antibodies.

THE VACCINE

ChAdOx1 nCoV-19, now known as AZD1222, was co-developed by the University of Oxford and one of its spin-off companies, Vaccitech. The vaccine uses a viral vector based on a common cold virus (adenovirus). This carries genetic material for the SARS-CoV-2 spike protein. In our previous blog, we saw how the spike proteins are used by the virus to target and fuse with our target cells, allowing the virus to invade, replicate and ultimately cause the disease known as COVID. It is also a good target for the human immune system to recognize and attack.

The viral vector delivers the genetic material inside our cells. The spike protein is then produced by our cells, recognized by the immune system as a viral target, and an immune response is created against it. This can be antibodies, which recognize, attach to and mark the virus in our blood, allowing for other white blood cells to destroy the virus.

In this case, the vaccine also produced a T cell response. T cells can recognize cells infected by a virus-based on the markers present on the surface of infected cells. They can tell an infected cell to destroy itself, thereby destroying the virus within without spreading the infection. They also have other functions that we will not discuss in this blog.

THE STUDY

This study was a Phase I/II trial that started in April using the vaccine named ChAdOx1 nCoV-19. This vaccine development started in January 2020, and progress on development has been incredibly rapid. Whilst our previous study had just 45 people, this study looked reviewed over 1,000 healthy adults. 10 of these participants received two doses of the vaccine.

In a study the more participants there are, the greater the power of the study. If the vaccine has any side effects, even ones that rarely occur, it is more likely to be picked up in studies with more people. Similarly having more people helps show that the vaccine is effective, and the strong responses are not merely a fluke or accident. Another benefit of this study is it was able to compare the vaccine against a control group. This shows the results were not simply a placebo and allowed comparison of side effects as well.

The majority of side effects were feeling feverish, chills, muscle ache, headache, and malaise, all symptoms treatable with paracetamol. None of the participants had any serious side effects. It took just 14 days to create a T cell response, and 28 days to make strong antibodies. In 91% of patients, this was enough to neutralize the COVID coronavirus. Receiving two doses gave an even stronger antibody response, and all participants were able to stop the virus.

WHAT NEXT

The news from the University of Oxford is needed, as infection rate and mortality continue to increase in countries such as the US and Brazil. The ability to induce an antibody response without causing harm to the patient shows we have made huge progress in the fight against COVID-19. Further Large scale Phase III trials been set up through a global partnership, and include studies in the US with over 30,000 patients, studies in children as well as some in low to middle-income countries.

If successful a vaccine would be essential in preventing a second wave of COVID in the winter when the elderly population is most at risk. And it would be the key to restarting the economy and getting our everyday lives back to where it was pre-pandemic.

Read Blog

Machine Learning in Healthcare India: A New Era of Predictive and Personalized Care

Machine learning is driving one of the biggest transformations in Indian healthcare. Machine learning in healthcare India is improving diagnostics, predicting diseases early, and enabling personalized treatment plans based on large volumes of medical data. India’s enormous population, diverse health patterns, and rising burden of lifestyle diseases make ML an essential technology for improving care outcomes.

SecondMedic integrates machine learning across diagnostics, risk scoring, preventive care, and remote monitoring to create intelligent, data-driven healthcare experiences.

Why Machine Learning Is Crucial for India’s Healthcare

India faces major challenges: increasing chronic diseases, low doctor-to-patient ratio, and gaps in early diagnosis. Machine learning helps overcome these limitations through automated analysis and predictive insights.

ML supports:

Accurate disease prediction
Faster diagnosis
Personalized treatment
Proactive health management
Population-level insights

These benefits significantly improve care outcomes.

Machine Learning in Diagnostics

ML excels at interpreting complex medical data faster than traditional methods.

ML improves diagnostics by:

Identifying abnormal patterns
Analyzing imaging scans
Interpreting lab values
Comparing historical trends
Supporting clinical decisions

This reduces misdiagnosis and saves time.

Predictive Healthcare with Machine Learning

Predictive analytics is one of the most powerful ML applications.

ML predicts risks for:

Heart disease
Diabetes
Kidney disorders
Thyroid imbalances
Mental health issues
Respiratory disorders

SecondMedic provides predictive scoring for early detection.

Personalized Treatment Planning

Machine learning tailors treatment to individual needs.

ML personalizes care based on:

Age and genetics
Lifestyle patterns
Vitals and wearable data
Sleep and stress levels
Previous medical history

This ensures more accurate and effective treatment.

ML in Remote Patient Monitoring

With the rise of home healthcare, ML analyzes continuous vitals data.

ML monitors:

Heart rate
Blood oxygen
Blood sugar
Blood pressure
Sleep cycles

AI-generated alerts support timely intervention.

ML in Medical Imaging

ML enhances imaging interpretation by detecting subtle visual patterns.

Applications include:

Lung infections
Cancer markers
Cardiac abnormalities
Brain lesions
Kidney anomalies

This improves radiology accuracy and speed.

ML for Population Health in India

ML identifies health trends at a large scale, helping policymakers and hospitals plan resources.

ML provides:

Outbreak prediction
Disease burden patterns
Community health insights
Regional risk mapping

These tools help improve national healthcare planning.

Challenges in ML Healthcare Adoption

While ML is powerful, challenges include:

Data quality issues
Need for clinical validation
Privacy concerns
Infrastructure limitations
Need for skilled professionals

SecondMedic follows ethical ML standards and ensures secure data practices.

Future of Machine Learning in Indian Healthcare

Upcoming innovations include:

Deep learning diagnostics
Digital health twins
Fully AI-driven preventive dashboards
ML-based robotic treatments
Genomic ML predictions

SecondMedic is committed to building future-ready ML healthcare solutions.

Conclusion

Machine learning in healthcare India is transforming medical care through predictive analytics, personalized treatment, and early disease detection. SecondMedic uses machine learning across its digital ecosystem to deliver accurate, efficient, and patient-centered care.

To explore ML-powered healthcare tools, visit www.secondmedic.com

References

NITI Aayog – AI & ML in Indian Healthcare
WHO – Machine Learning in Clinical Practice
ICMR – India Chronic Disease Data
IMARC – AI & ML Healthcare India
FICCI – Emerging Health Technologies India

Request A Callback

+91

By using this website/app, I confirm that I am at least 18 years old and consent to the processing of my personal data in accordance with the Terms of Service, Privacy Policy, and Declaration.